로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Antibody > SN38 > SN8-S223

Monoclonal Anti-SN38 Antibody (MALS verified)

  • Source
    Monoclonal Anti-SN38 Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with SN38.
  • Isotype
    Mouse IgG1/kappa
  • Specificity
    Specifically recognizes the target-SN38.
  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
SN38 SDS-PAGE

Monoclonal Anti-SN38 Antibody on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
SN38 MALS images

The purity of Monoclonal Anti-SN38 Antibody (Cat. No. SN8-S223) is more than 95% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.

Bioactivity-Elisa
 SN38 ELISA

Immobilized ADC-SN38 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SN38 Antibody (Cat. No. SN8-S223) with a linear range of 0.05-1.56 ng/mL (QC tested).

  • Background
    SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 924,000

가격(KRW) : 6,148,500

보급 및 전시



Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop